Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LPS002
MIFTS: 64

Liposarcoma

Categories: Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liposarcoma

About this section

MalaCards integrated aliases for Liposarcoma:

Name: Liposarcoma 12 74 20 54 44 15 17 71

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Liposarcoma

About this section
GARD : 20 Liposarcoma is a tumor that arises from fat tissue. This tumor often occurs in the thigh, legs, behind the knee, or in the abdomen, but it can be found in other parts of the body, in the retroperitoneum; and, less often, in the head and neck area. Their primary occurrence in the skin is rare. Because a liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor. The World Health Organization classification of soft tissue tumors recognizes 5 types of liposarcomas: Well differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; dedifferentiated; myxoid; round cell; and pleomorphic. Most patients with liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems. Although surgical removal of the tumor is the curative treatment, some patients may benefit from chemotherapy and radiation. Most patients with liposarcoma have no symptoms until the tumor is large and impinges on neighboring structures, causing tenderness, pain, or functional disturbances. In the retroperitoneal area, where liposarcoma is detected at a late stage, the tumor may grow to a substantial size, weighing several pounds at the time of diagnosis. In general, liposarcoma grows silently, and the patient's estimation of the clinical duration is often unreliable. The patient eventually becomes aware of a swelling or a mass and reports this finding to the physician. Patients may report the following: Associated episode of trauma to the region containing the mass Painful swelling (occurs in one third of cases for as long as 6 mo) Decreased function (ie, range of motion) Numbness Enlargement of varicose veins Fatigue Abdominal pain Weight loss Nausea Vomiting

MalaCards based summary : Liposarcoma is related to myxoid liposarcoma and mediastinum liposarcoma. An important gene associated with Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Endometrial cancer. The drugs Dacarbazine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include t cells, tongue and colon, and related phenotypes are subcutaneous nodule and sarcoma

Disease Ontology : 12 A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities.

Wikipedia : 74 Liposarcoma is a cancer that arises in fat cells in soft tissue, such as that inside the thigh or in the... more...

Sources

Related Diseases for Liposarcoma

About this section

Diseases in the Liposarcoma family:

Adult Liposarcoma Inflammatory Liposarcoma

Diseases related to Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 648)
# Related Disease Score Top Affiliating Genes
1 myxoid liposarcoma 32.8 YBX1 TSN TP53 MDM2 LRP1 HMGA2
2 mediastinum liposarcoma 32.7 MDM2 CDKN2A CDK4
3 cellular myxoid liposarcoma 32.6 MDM2 FUS EWSR1 DDIT3 CDK4
4 gastric liposarcoma 32.5 MDM2 CDK4 CD34
5 mixed liposarcoma 32.5 MDM2 FUS DDIT3 CDK4 CD34
6 well-differentiated liposarcoma 32.5 TP53 MDM2 HMGA2 FUS EWSR1 DDIT3
7 sclerosing liposarcoma 32.4 MDM2 FUS CD34
8 liposarcoma of bone 32.4 MDM2 CDK4 CD34
9 adult liposarcoma 32.4 MDM2 CDK4
10 inflammatory liposarcoma 32.4 MDM2 CDKN2A CD34
11 pleomorphic liposarcoma 32.4 VIM MDM2 FUS EWSR1 DES DDIT3
12 spindle cell liposarcoma 32.3 MDM2 DDIT3 CDK4 CD34
13 pediatric liposarcoma 32.0 VIM MDM2 HMGA2 FUS DDIT3 CDK4
14 dedifferentiated liposarcoma 31.9 TP53 RB1 PPARG MDM2 MB HMGA2
15 pleomorphic lipoma 31.9 MDM2 HMGA2 CDK4 CD34
16 soft tissue sarcoma 31.7 TP53 MDM2
17 lipomatosis, multiple 31.6 MDM2 HMGA2 FUS EWSR1 DES DDIT3
18 rare tumor 31.4 EWSR1 DES
19 fibrous histiocytoma 31.3 VIM FUS EWSR1 DES CD34
20 retroperitoneal sarcoma 31.2 MDM2 CDK4 CD34
21 malignant fibrous histiocytoma 31.2 VIM TP53 MDM2 MB EWSR1 DES
22 mesenchymal cell neoplasm 31.1 TP53 HMGA2 EWSR1 CD34
23 fibrosarcoma 31.1 VIM TP53 FUS EWSR1 DES
24 spindle cell sarcoma 31.1 VIM MDM2 GPS2 EWSR1 DES CD34
25 osteogenic sarcoma 31.0 TP53 RB1 MDM2 CDKN2A CDK4
26 lipoblastoma 31.0 MDM2 CDK4
27 malignant mesenchymoma 30.9 MDM2 MB DES CD34
28 sarcoma 30.9 VIM TP53 RB1 MDM2 FUS EWSR1
29 myxofibrosarcoma 30.9 TP53 MDM2 FUS EWSR1 DES DDIT3
30 chondrosarcoma 30.8 VIM MDM2 EWSR1 CDK4
31 infiltrating lipoma 30.8 MDM2 HMGA2 CDK4 CD34
32 embryonal sarcoma 30.8 VIM TP53 MDM2 DES CDK4
33 leiomyosarcoma 30.8 VIM TP53 RB1 MDM2 MB HMGA2
34 leiomyoma 30.8 VIM HMGA2 DES CD34
35 spindle cell lipoma 30.7 VIM RB1 MDM2 DES CDK4 CD34
36 gastrointestinal stromal tumor 30.7 VIM TP53 DES CDKN2A CD34
37 li-fraumeni syndrome 30.7 TP53 RB1 MDM2 CDKN2A CDK4
38 angiolipoma 30.6 VIM MDM2 DES CD34
39 retinoblastoma 30.6 TP53 RB1 PPARG MDM2 CDKN2A CDK4
40 neurofibroma 30.6 VIM TP53 CDKN2A CD34
41 chondroid lipoma 30.5 HMGA2 FUS
42 hemangiopericytoma, malignant 30.5 VIM MDM2 DES CD34
43 benign mesothelioma 30.5 VIM CDKN2A CD34 CALB2
44 angiosarcoma 30.5 VIM TP53 CD34 CALB2
45 connective tissue benign neoplasm 30.5 TP53 MDM2 EWSR1 CDK4 CD34 CALB2
46 neurilemmoma 30.4 VIM DES CD34 CALB2
47 retroperitoneal fibrosis 30.4 VIM MDM2
48 malignant peripheral nerve sheath tumor 30.4 VIM TP53 MDM2 HMGA2 CDKN2A CDK4
49 rhabdomyosarcoma 30.4 VIM TP53 RB1 MDM2 MB HMGA2
50 adenocarcinoma 30.4 TP53 RB1 MDM2 CDKN2A CDK4

Graphical network of the top 20 diseases related to Liposarcoma:



Diseases related to Liposarcoma
Sources

Symptoms & Phenotypes for Liposarcoma

About this section

Human phenotypes related to Liposarcoma:

31 (show all 9)
# Description HPO Frequency HPO Source Accession
1 subcutaneous nodule 31 hallmark (90%) HP:0001482
2 sarcoma 31 hallmark (90%) HP:0100242
3 nausea and vomiting 31 occasional (7.5%) HP:0002017
4 fatigue 31 occasional (7.5%) HP:0012378
5 abdominal pain 31 occasional (7.5%) HP:0002027
6 paresthesia 31 occasional (7.5%) HP:0003401
7 varicose veins 31 occasional (7.5%) HP:0002619
8 abnormality of the kidney 31 occasional (7.5%) HP:0000077
9 weight loss 31 occasional (7.5%) HP:0001824

GenomeRNAi Phenotypes related to Liposarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CD34 CDK4 DDIT3 DES MDM2 PPARG

MGI Mouse Phenotypes related to Liposarcoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 CD34 CDK4 CDKN2A DDIT3 DES LRP1
2 cardiovascular system MP:0005385 10.29 CDK4 CDKN2A DDIT3 DES LRP1 MB
3 behavior/neurological MP:0005386 10.27 CALB2 CDK4 CDKN2A DDIT3 DES LRP1
4 homeostasis/metabolism MP:0005376 10.24 CD34 CDK4 CDKN2A DDIT3 DES LRP1
5 hematopoietic system MP:0005397 10.22 CD34 CDK4 CDKN2A DDIT3 LRP1 MB
6 embryo MP:0005380 10.13 CDK4 CDKN2A LRP1 MB MDM2 PPARG
7 immune system MP:0005387 10.1 CD34 CDK4 CDKN2A DDIT3 LRP1 MDM2
8 integument MP:0010771 9.91 CD34 CDK4 CDKN2A MDM2 PPARA PPARG
9 liver/biliary system MP:0005370 9.85 CDK4 CDKN2A DDIT3 LRP1 MDM2 PPARA
10 muscle MP:0005369 9.7 CDK4 CDKN2A DES LRP1 MB MDM2
11 neoplasm MP:0002006 9.23 CD34 CDK4 CDKN2A DDIT3 MDM2 PPARG
Sources

Drugs & Therapeutics for Liposarcoma

About this section

Drugs for Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166 2942
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3 Olaratumab Approved, Investigational Phase 3 1024603-93-7
4
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
5
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
6
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
7 Antibiotics, Antitubercular Phase 3
8 Anti-Bacterial Agents Phase 3
9
Liposomal doxorubicin Phase 3 31703
10
Isophosphamide mustard Phase 2, Phase 3 100427
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
13
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
14
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
15
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
16
Bevacizumab Approved, Investigational Phase 2 216974-75-3
17
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
20
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
21
Gemcitabine Approved Phase 2 95058-81-4 60750
22
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
23
Lenvatinib Approved, Investigational Phase 1, Phase 2 417716-92-8
24
Durvalumab Approved, Investigational Phase 2 1428935-60-7
25
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
Mesna Approved, Investigational Phase 2 3375-50-6 598
28
nivolumab Approved Phase 2 946414-94-4
29
Ipilimumab Approved Phase 2 477202-00-9
30
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
31
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
32
Nelfinavir Approved Phase 1, Phase 2 159989-64-7 64143
33
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
34
Maleic acid Experimental Phase 2 110-16-7 444266
35
Saracatinib Investigational Phase 2 379231-04-6
36
Efatutazone Investigational Phase 2 223132-37-4
37
Varespladib methyl Investigational Phase 2 172733-08-3
38 Imatinib Mesylate Phase 2 220127-57-1 123596
39 Anti-Inflammatory Agents Phase 2
40 Gastrointestinal Agents Phase 2
41 Hormones Phase 2
42 Hormone Antagonists Phase 2
43 Antineoplastic Agents, Hormonal Phase 2
44 Antiemetics Phase 2
45 glucocorticoids Phase 2
46 Angiogenesis Inhibitors Phase 2
47 BB 1101 Phase 2
48 Hypoglycemic Agents Phase 2
49 Protein Kinase Inhibitors Phase 2
50 Antifungal Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
2 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
3 Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
4 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Recruiting NCT04031677 Phase 3 Preoperative chemotherapy
5 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
6 A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Active, not recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
7 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
8 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
9 GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
10 A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation Unknown status NCT00633165 Phase 2 Brostallicin
11 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
12 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT03096912 Phase 2 Ribociclib
13 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
14 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
15 A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis) in Patients With Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
16 Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma Completed NCT01841047 Phase 2
17 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
18 A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
19 A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2 pazopanib
20 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
21 Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists Completed NCT01692496 Phase 2 Pazopanib
22 A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2 Palbociclib 200mg;Palbociclib 125mg
23 Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
24 Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma Completed NCT00003058 Phase 2 troglitazone
25 A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma Completed NCT00093080 Phase 2 ridaforolimus
26 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
27 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
28 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
29 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
30 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Completed NCT01532687 Phase 2 Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
31 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
32 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
33 A Single Arm, Multi Centers, Phase II Study of Sintilimab, Doxorubicin and Ifosfamide at First-line Treatment of Soft Tissue Sarcoma Including Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, Myxoid Liposarcoma and De-differentiated Liposarcoma Recruiting NCT04356872 Phase 2 Sintilimab;Doxorubicin Hydrochloride;Ifosfamide
34 A Phase 2, Single Arm, Multi Center Trial Evaluating the Efficacy of the COmbination of Sirolimus and cYclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and chOndrosarcoma Recruiting NCT02821507 Phase 2 sirolimus and cyclophosphamide
35 A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Recruiting NCT04044768 Phase 2
36 A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Recruiting NCT02992743 Phase 2
37 Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Recruiting NCT02275286 Phase 1, Phase 2 Trabectedin
38 SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN as First Line Treatment of Advanced Soft Tissue Sarcoma (STS) Recruiting NCT03138161 Phase 1, Phase 2 Trabectedin;Ipilimumab;Nivolumab
39 SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Recruiting NCT02048371 Phase 2 Regorafenib;Placebo
40 A Phase II Trial of Sitravatinib (MGCD516), a Multi-receptor Tyrosine Kinase Inhibitor, in Advanced Liposarcoma and Other Soft Tissue Sarcomas Recruiting NCT02978859 Phase 2 MGCD516
41 A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated and/or Dedifferentiated Liposarcoma Recruiting NCT04438824 Phase 2 INCMGA00012;Palbociclib
42 Open-label, Phase II Trial of Eribulin in Combination With Gemcitabine in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma Recruiting NCT03810976 Phase 2 Eribulin, gemcitabine
43 Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Recruiting NCT03114527 Phase 2 Ribociclib;Everolimus
44 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
45 A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study) Recruiting NCT03526679 Phase 1, Phase 2 Eribulin;Lenvatinib
46 A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma Subtypes Recruiting NCT04668300 Phase 2
47 A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors Recruiting NCT03611868 Phase 1, Phase 2 APG-115+Pembrolizumab
48 A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors Recruiting NCT03425279 Phase 1, Phase 2
49 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Recruiting NCT03899805 Phase 2 Eribulin;Pembrolizumab
50 A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Recruiting NCT02923778 Phase 2

Search NIH Clinical Center for Liposarcoma

Cochrane evidence based reviews: liposarcoma

Sources

Genetic Tests for Liposarcoma

About this section
Sources

Anatomical Context for Liposarcoma

About this section

MalaCards organs/tissues related to Liposarcoma:

40
T Cells, Tongue, Colon, Pancreas, Bone, Prostate, Lymph Node
Sources

Publications for Liposarcoma

About this section

Articles related to Liposarcoma:

(show top 50) (show all 5872)
# Title Authors PMID Year
1
Neuronal death in amyotrophic lateral sclerosis (ALS): what can we learn from genetics? 54 61
20406185 2010
2
The role of autophagy: what can be learned from the genetic forms of amyotrophic lateral sclerosis. 61 54
20406184 2010
3
Protein aggregation and defective RNA metabolism as mechanisms for motor neuron damage. 54 61
20406182 2010
4
Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases. 61 54
20228779 2010
5
[Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation]. 54 61
19823827 2010
6
Well-differentiated and dedifferentiated liposarcomas. 61 54
19688222 2010
7
Specificity of fusion genes in adipocytic tumors. 61 54
20332486 2010
8
Significance of LRP and PPAR-gamma Expression in Lipomatous Soft Tissue Tumors. 54 61
20224740 2010
9
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. 54 61
19946100 2009
10
Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. 61 54
19820690 2009
11
Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. 54 61
19734852 2009
12
Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. 61 54
19626636 2009
13
Pseudosarcomatous fibroblastic/myofibroblastic proliferation in perinephric adipose tissue adjacent to renal cell carcinoma: a lesion mimicking well-differentiated liposarcoma. 54 61
19525929 2009
14
Rhabdomyomatous well-differentiated liposarcoma arising in giant fibrovascular polyp of the esophagus. 61 54
19608085 2009
15
Structural basis and specificity of human otubain 1-mediated deubiquitination. 61 54
18954305 2009
16
Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. 61 54
18820664 2009
17
Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. 61 54
18836421 2009
18
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. 54 61
18500263 2008
19
Mixed-type liposarcoma: clinicopathological, immunohistochemical, and molecular analysis of a case arising in deep soft tissues of the lower extremity. 61 54
18551309 2008
20
SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. 61 54
18580682 2008
21
FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. 54 61
18596980 2008
22
Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. 61 54
18509338 2008
23
[Retroperitoneal giant mixed sarcoma. Case report]. 54 61
18507961 2008
24
Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. 61 54
18204431 2008
25
High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. 61 54
18414473 2008
26
Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma. 61 54
18438568 2008
27
Clinical Use of PPARgamma Ligands in Cancer. 61 54
19125177 2008
28
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. 54 61
17638873 2007
29
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. 61 54
17359542 2007
30
Pathology and genetics of adipocytic tumors. 54 61
18000364 2007
31
Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. 54 61
17214366 2006
32
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. 54 61
17018606 2006
33
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. 61 54
16707369 2006
34
Calretinin expression in tumors of adipose tissue. 61 54
16613326 2006
35
A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. 61 54
16405554 2006
36
Round cell liposarcoma of scrotum with indolent course in young adult. 61 54
16536120 2005
37
Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. 54 61
15688424 2005
38
Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. 54 61
15551306 2005
39
Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. 61 54
15064749 2004
40
[From cytogenetics to cytogenomics of adipose tissue tumors: 2. Malignant adipose tissue tumors]. 54 61
15242313 2004
41
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. 61 54
12551936 2003
42
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 54 61
12640106 2003
43
Different mRNA expression profile during tumor progression in a well-differentiated liposarcoma--A microdissection approach. 54 61
12924448 2003
44
Current strategies for anticancer chemoprevention and chemoprotection. 54 61
12669776 2002
45
Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. 54 61
12353276 2002
46
A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma. 54 61
12169678 2002
47
RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. 61 54
12168660 2002
48
The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. 54 61
11604390 2001
49
PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. 54 61
11494023 2001
50
Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). 54 61
11530334 2001
Sources

Variations for Liposarcoma

About this section

Cosmic variations for Liposarcoma:

9 (show top 50) (show all 964)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102046780 ZFHX3 soft tissue,fat,liposarcoma,myxoid-round cell c.-23-8733C>A p.? 16:72959698-72959698 12
2 COSM87295767 ZFHX3 soft tissue,fat,liposarcoma,myxoid-round cell c.448C>A p.L150M 16:72959698-72959698 12
3 COSM149329806 ZFHX3 soft tissue,fat,liposarcoma,myxoid-round cell c.448C>A p.L150M 16:72959698-72959698 12
4 COSM101976918 XPO1 soft tissue,fat,liposarcoma,myxoid-round cell c.1288G>T p.V430L 2:61493011-61493011 12
5 COSM104882729 XPO1 soft tissue,fat,liposarcoma,myxoid-round cell c.1288G>T p.V430L 2:61493011-61493011 12
6 COSM104236189 XPO1 soft tissue,fat,liposarcoma,myxoid-round cell c.1288G>T p.V430L 2:61493011-61493011 12
7 COSM113483043 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.427G>A p.E143K 11:32434919-32434919 12
8 COSM111536922 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.427G>A p.E143K 11:32434919-32434919 12
9 COSM147424156 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.427G>A p.E143K 11:32434919-32434919 12
10 COSM148591018 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.427G>A p.E143K 11:32434919-32434919 12
11 COSM91381057 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.427G>A p.E143K 11:32434919-32434919 12
12 COSM149737803 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.427G>A p.E143K 11:32434919-32434919 12
13 COSM151895912 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
14 COSM111040244 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
15 COSM149038920 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
16 COSM150677027 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
17 COSM150523552 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
18 COSM102541613 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.*317C>A p.? 9:132911064-132911064 12
19 COSM151103730 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1122C>A p.N374K 9:132911064-132911064 12
20 COSM148791748 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
21 COSM151333783 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
22 COSM85719005 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
23 COSM133086425 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.926C>A p.T309N 9:132911064-132911064 12
24 COSM148033864 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
25 COSM150536467 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.926C>A p.T309N 9:132911064-132911064 12
26 COSM147982566 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
27 COSM148126195 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
28 COSM151874979 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
29 COSM143166781 TP53 soft tissue,fat,liposarcoma,pleomorphic c.100C>T p.H34Y 17:7674954-7674954 12
30 COSM144086975 TP53 soft tissue,fat,liposarcoma,pleomorphic c.47G>A p.R16H 17:7675088-7675088 12
31 COSM145017326 TP53 soft tissue,fat,liposarcoma,pleomorphic c.407G>A p.R136H 17:7675088-7675088 12
32 COSM144093313 TP53 soft tissue,fat,liposarcoma,pleomorphic c.-74G>T p.? 17:7675208-7675208 12
33 COSM144092386 TP53 soft tissue,fat,liposarcoma,pleomorphic c.16C>T p.Q6* 17:7675119-7675119 12
34 COSM144650780 TP53 soft tissue,fat,liposarcoma,pleomorphic c.407G>A p.R136H 17:7675088-7675088 12
35 COSM143950195 TP53 soft tissue,fat,liposarcoma,pleomorphic c.16C>T p.Q6* 17:7675119-7675119 12
36 COSM144319814 TP53 soft tissue,fat,liposarcoma,pleomorphic c.460C>T p.H154Y 17:7674954-7674954 12
37 COSM144013725 TP53 soft tissue,fat,liposarcoma,pleomorphic c.674A>G p.Y225C 17:7674256-7674256 12
38 COSM144057703 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.163C>T p.H55Y 17:7674891-7674891 12
39 COSM143164007 TP53 soft tissue,fat,liposarcoma,pleomorphic c.-74G>T p.? 17:7675208-7675208 12
40 COSM105689492 TP53 soft tissue,fat,liposarcoma,pleomorphic c.421T>G p.C141G 17:7675191-7675191 12
41 COSM142842779 TP53 soft tissue,fat,liposarcoma,pleomorphic c.493C>T p.Q165* 17:7675119-7675119 12
42 COSM106084061 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 17:7675113-7675113 12
43 COSM143489189 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.523C>T p.H175Y 17:7674891-7674891 12
44 COSM142846305 TP53 soft tissue,fat,liposarcoma,pleomorphic c.577C>T p.H193Y 17:7674954-7674954 12
45 COSM145025367 TP53 soft tissue,fat,liposarcoma,pleomorphic c.376C>T p.Q126* 17:7675119-7675119 12
46 COSM122271291 TP53 soft tissue,fat,liposarcoma,pleomorphic c.128G>A p.R43H 17:7675088-7675088 12
47 COSM145045823 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.382C>T p.Q128* 17:7675113-7675113 12
48 COSM112265244 TP53 soft tissue,fat,liposarcoma,pleomorphic c.577C>T p.H193Y 17:7674954-7674954 12
49 COSM111885157 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 17:7674891-7674891 12
50 COSM111790424 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 17:7675113-7675113 12

Copy number variations for Liposarcoma from CNVD:

7 (show all 36)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13334 1 1 124300000 Gain Liposarcoma
2 16445 1 124300000 247249719 Loss Liposarcoma
3 20078 1 15300000 163800000 Amplification NBPF12 Liposarcoma
4 20079 1 15300000 163800000 Amplification PPIAL4A Liposarcoma
5 20080 1 15300000 163800000 Amplification PFN1P2 Liposarcoma
6 20084 1 15300000 212100000 Gain Liposarcoma
7 42815 10 40300000 135374737 Loss Liposarcoma
8 55437 11 52900000 134452384 Loss Liposarcoma
9 61489 12 1 14800000 Loss Liposarcoma
10 67172 12 37282278 37312244 Amplified DDIT3 Liposarcoma
11 67787 12 44600000 69800000 Gain CDK4 liposarcomas
12 67788 12 44600000 69800000 Gain HMGA2 liposarcomas
13 67789 12 44600000 69800000 Gain MDM2 liposarcomas
14 69651 12 56140200 56152312 Amplified GLI1 Liposarcoma
15 69861 12 56374152 56401607 Amplified OS9 Liposarcoma
16 69873 12 56425050 56428293 Amplified TSPAN31 Liposarcoma
17 69880 12 56428269 56432431 Amplified CDK4 Liposarcoma
18 70737 12 64503703 64646338 Amplified HMGA2 Liposarcoma
19 71088 12 67488246 67520481 Amplified MDM2 Liposarcoma
20 77049 13 39500000 52200000 Loss Liposarcoma
21 77649 13 46200000 52200000 Deletion RB1 Liposarcoma
22 78496 13 52200000 114142980 Loss Liposarcoma
23 106733 17 1 11200000 Deletion Liposarcoma
24 108852 17 23200000 28800000 Deletion Liposarcoma
25 139560 2 183406981 183439743 Amplified FRZB Liposarcoma
26 149783 2 93300000 242951149 Gain Liposarcoma
27 149786 2 93300000 242951149 Loss Liposarcoma
28 166153 3 1 91700000 Gain Liposarcoma
29 166161 3 1 91700000 Loss Liposarcoma
30 179460 3 91700000 199501827 Gain Liposarcoma
31 187537 4 50700000 191273063 Loss Liposarcoma
32 191663 5 1 45800000 Gain Liposarcoma
33 200009 5 47700000 180857866 Gain Liposarcoma
34 210239 6 29900000 45200000 Gain Liposarcoma
35 217105 7 1 59100000 Gain Liposarcoma
36 225569 7 47600000 107200000 Gain Liposarcoma
Sources

Expression for Liposarcoma

About this section
Search GEO for disease gene expression data for Liposarcoma.
Sources

Pathways for Liposarcoma

About this section

Pathways related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Cellular Senescence (REACTOME) 65
Show member pathways
 13.09 TP53 RB1 MDM2 HMGA2 CDKN2A CDK4
2
Endometrial cancer 36
Show member pathways
 12.8 TP53 RB1 PPARG MDM2 CDKN2A CDK4
3
Measles 36
Show member pathways
 12.77 VIM TP53 RB1 MDM2 CDK4
4
Pathways in cancer 36
12.77 TP53 RB1 PPARG MDM2 CDKN2A CDK4
5
Glioma 36
Show member pathways
 12.63 TP53 RB1 MDM2 CDKN2A CDK4
6
Mitotic G1-G1/S phases 65
Show member pathways
 12.51 TP53 RB1 MDM2 CDKN2A CDK4
7
MicroRNAs in cancer 36
12.48 VIM TP53 MDM2 HMGA2 CDKN2A
8
DNA Damage 4
12.35 VIM TP53 RB1 MDM2 CDKN2A CDK4
9
Cyclins and Cell Cycle Regulation 63
Show member pathways
 12.31 TP53 RB1 CDKN2A CDK4
10
DNA Damage Response 1
Show member pathways
 12.31 TP53 RB1 MDM2 CDKN2A CDK4
11
Cell cycle 36 1
12.28 TP53 RB1 MDM2 CDKN2A CDK4
13
Translational Control 4
12.23 YBX1 FUS EWSR1 DDIT3
14
Human T-cell leukemia virus 1 infection 36
12.22 TP53 RB1 GPS2 CDKN2A CDK4
15
p53 Signaling 63
Show member pathways
 12.21 TP53 RB1 MDM2 CDK4
16
Viral carcinogenesis 36
12.16 TP53 RB1 MDM2 CDKN2A CDK4
17
Integrated Breast Cancer Pathway 1
12.1 TP53 RB1 MDM2 CDK4
18
Cellular senescence (KEGG) 36
12.02 TP53 RB1 MDM2 CDKN2A CDK4
19
Adipogenesis 1
12.01 RB1 PPARG PPARA DDIT3
20
Spinal Cord Injury 1
11.94 VIM TP53 RB1 CDK4
21
Senescence and Autophagy in Cancer 1
11.87 TP53 RB1 MDM2 CDKN2A
22
Small cell lung cancer 36
11.81 TP53 RB1 CDK4
23
Glioblastoma Multiforme 63
11.76 TP53 RB1 MDM2 CDKN2A CDK4
24
Retinoblastoma (RB) in Cancer 1
11.74 TP53 RB1 MDM2 CDK4
25
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.7 TP53 MDM2 CDKN2A
26
Platinum drug resistance 36
11.7 TP53 MDM2 CDKN2A
27
Transcription_P53 signaling pathway 23
11.66 TP53 RB1 MDM2 CDKN2A
28
Regulation of retinoblastoma protein 1
11.56 RB1 PPARG MDM2
29
HIF1Alpha Pathway 63
11.54 TP53 MDM2 CDKN2A
30
Photodynamic therapy-induced AP-1 survival signaling. 1
11.5 TP53 RB1 CDKN2A
31
Transcriptional misregulation in cancer 36
11.45 TP53 PPARG MDM2 HMGA2 FUS EWSR1
32
DNA damage_ATM/ATR regulation of G1/S checkpoint 23
11.42 TP53 MDM2 CDK4
33
Bladder cancer 36 1
11.42 TP53 RB1 MDM2 CDKN2A CDK4
34
Integrated Cancer Pathway 1
11.33 TP53 RB1 MDM2 CDK4
35
Oncogene Induced Senescence 65
11.06 TP53 MDM2 CDKN2A CDK4
36
TP53 Network 1
Show member pathways
 11.03 TP53 MDM2 CDKN2A
37
Inhibition of Ribosome Biogenesis by p14(ARF) 63
10.6 TP53 RB1 MDM2 CDKN2A
Sources

GO Terms for Liposarcoma

About this section

Cellular components related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.13 YBX1 VIM TSN TP53 PPARG MDM2
2 cytoplasm GO:0005737 10.06 YBX1 VIM TSN TP53 PPARG MDM2
3 chromatin GO:0000785 9.95 TP53 RB1 PPARG PPARA HMGA2 DDIT3
4 nucleoplasm GO:0005654 9.8 YBX1 TSN TP53 RB1 PPARG PPARA
5 transcription factor complex GO:0005667 9.67 TP53 RB1 DDIT3 CDK4
6 nucleus GO:0005634 9.58 YBX1 VIM TSN TP53 RB1 PPARG
7 senescence-associated heterochromatin focus GO:0035985 9.26 HMGA2 CDKN2A

Biological processes related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 10.02 TP53 RB1 HMGA2 DDIT3 CDKN2A CDK4
2 positive regulation of apoptotic process GO:0043065 9.96 TP53 PPARG HMGA2 CDKN2A CDK4
3 heart development GO:0007507 9.91 TP53 PPARG PPARA MDM2
4 regulation of transcription, DNA-templated GO:0006355 9.91 YBX1 TP53 RB1 PPARG PPARA HMGA2
5 positive regulation of transcription, DNA-templated GO:0045893 9.87 TP53 PPARG PPARA HMGA2 FUS DDIT3
6 positive regulation of gene expression GO:0010628 9.85 VIM TP53 MDM2 HMGA2 CDKN2A CD34
7 negative regulation of inflammatory response GO:0050728 9.81 RB1 PPARG PPARA GPS2
8 cell cycle arrest GO:0007050 9.8 TP53 RB1 DDIT3 CDKN2A
9 Ras protein signal transduction GO:0007265 9.77 TP53 RB1 CDKN2A
10 negative regulation of neuron projection development GO:0010977 9.77 VIM MDM2 LRP1
11 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.76 RB1 CDKN2A CDK4
12 negative regulation of cell growth GO:0030308 9.73 TP53 RB1 PPARG CDKN2A
13 negative regulation of transcription, DNA-templated GO:0045892 9.7 TP53 RB1 PPARG MDM2 HMGA2 DDIT3
14 negative regulation of telomerase activity GO:0051974 9.64 TP53 PPARG
15 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.63 PPARG PPARA
16 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.63 TP53 DDIT3
17 amyloid fibril formation GO:1990000 9.62 MDM2 CDKN2A
18 ER overload response GO:0006983 9.62 TP53 DDIT3
19 negative regulation of cholesterol storage GO:0010887 9.61 PPARG PPARA
20 cellular response to UV-C GO:0071494 9.58 TP53 MDM2
21 positive regulation of cell cycle arrest GO:0071158 9.58 TP53 HMGA2 CDKN2A
22 positive regulation of fatty acid oxidation GO:0046321 9.57 PPARG PPARA
23 negative regulation of transcription by RNA polymerase II GO:0000122 9.56 TP53 RB1 PPARG PPARA MDM2 HMGA2
24 positive regulation of fatty acid metabolic process GO:0045923 9.54 PPARG PPARA
25 negative regulation of sequestering of triglyceride GO:0010891 9.52 PPARG PPARA
26 cellular response to actinomycin D GO:0072717 9.48 TP53 MDM2
27 senescence-associated heterochromatin focus assembly GO:0035986 9.46 HMGA2 CDKN2A
28 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 YBX1 TP53 RB1 PPARG PPARA MDM2

Molecular functions related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.02 YBX1 TSN TP53 RB1 PPARG PPARA
2 identical protein binding GO:0042802 9.91 VIM TSN TP53 RB1 PPARG MDM2
3 transcription regulatory region sequence-specific DNA binding GO:0000976 9.71 TP53 PPARG HMGA2 DDIT3
4 p53 binding GO:0002039 9.54 TP53 MDM2 CDKN2A
5 MDM2/MDM4 family protein binding GO:0097371 9.33 TP53 PPARA CDKN2A
6 disordered domain specific binding GO:0097718 9.26 TP53 RB1 MDM2 CDKN2A
7 transcription factor binding GO:0008134 9.23 TP53 RB1 PPARG PPARA HMGA2 DDIT3
Sources

Sources for Liposarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....